The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Abstract Background There are numerous non-biologic and biologic disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA). Typical sequences of bDMARDs are not clear. Future treatment policies and trials should be informed by quantitative estimates of current treatment practice...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-020-02408-4 |